HomeThemesTypesDBAbout
Showing: ◈ medicine×
EU moves to guarantee supply of medicines to Northern Ireland have so far worked but there are looming issues, peers have heard.
A House of Lords committee will discuss the impact of the Northern Ireland protocol on medicine supplies in Northern Ireland.
Sir Reg Empey says he expects a hearing into how the NI Protocol is affecting medicine supplies on Wednesday to bring “more bad news”.
An organisation which represents medicines wholesalers says supplying Northern Ireland remains "challenging, problematic and inefficient".
THE turning point was the Brexit referendum. Before voting to leave the EU in June 2016, medicine shortages were not something the UK often had to worry about.
The Nuffield Trust think tank has published a new report on the impact of Brexit on the UK’s health and care services. The ongoing monitoring work, funded by the Health Foundation, covers the impact on the NHS and social care workforce, medicine and medical devices supply and the economic cost, and reveals negative effects across these areas.
The impact of Brexit has only added fuel to the fire of severe challenges facing health and social care in the UK, warns the Nuffield Trust.
Specialisms such as dentistry have shortages and EU exit still causes issues with medicines in Northern Ireland, thinktank finds.
There are growing post-Brexit differences between which medicines are approved for use in Northern Ireland and the rest of the UK, research from a health think tank indicates.
Sam Bright examines the contribution of Brexit to our current healthcare crisis.
The shortage of medicines is set to only get worse in Ireland because stockpiles created to lessen the impact of Brexit are running out, the chair of Medicines for Ireland has warned.
THE SEISMIC CHANGES to the relationship with our nearest neighbours and the impact of Brexit have only added fuel to the fire of severe challenges facing health and social care in the UK today, making people less healthy and widening health inequalities.
Brexit has increased drug prices and worsened staff shortages in the U.K., increasing the impact of other serious issues facing the country’s health care system, a report has found.
The UK's split with the EU has worsened recruitment shortages while pushing up the price of some medicines.
Brexit shut off the “relief valve” of immigration from the European Union, worsening workforce shortages in health and social care in the UK, a report from the Nuffield Trust think tank has concluded. / Brexit’s effect has been felt particularly in specialties such as cardiothoracic surgery and anaesthesia, and in dentistry and the care sector.
Supplies of half of all veterinary drugs at risk due to restrictions on importing medicines from Britain.
There are still unresolved issues with the Northern Ireland Protocol despite changes made by the EU, says a major pharmaceutical firm.
The European Commission welcomes the swift adoption by the Council of the proposals to ensure the continued long-term supply of medicines from Great Britain to Northern Ireland and to address outstanding supply concerns in Cyprus, Ireland and Malta – markets that have been historically supplied through or by Great Britain.
India supplies the NHS with a quarter of its medicines and changes to pharma monopoly rights and patent laws under leaked plans could see costs spiral.
EXPORTS to the EU from Scotland have slumped by over £2.2bn since Brexit.
A complete shortage of a blood thinner drug dose is recorded in Cyprus due to Brexit, with health officials urging patients to show solidarity and buy only what they need. / Almost two years after the UK ceased being a member of the European Union, the island is still experiencing the consequences in its pharmaceutical sector.
In rejecting EU funding programmes, Britain has jeopardised research and made itself far less attractive to overseas scientists.
Was the United Kingdom’s move to exit the European Union (EU) via BREXIT a bad move for biomedical research? According to a prominent academic investigator from the Imperial College of London, the move cost 2.5 million Euros ($2.52m USD) in research grants.
As of December 2022, UK companies importing medicines from the EU may need to set up new batch testing facilities. What will this mean for the industry and how did the situation come about?
Six years after the referendum we can disentangle the evidence and judge the effects on health and care, says Richard Vize.